Skip to content

Back to Basics - Effects, Narratives and Routes of Administration of Open-label Placebo

Back to Basics - Effects, Narratives and Routes of Administration of Open-label Placebo

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02578420
Enrollment
160
Registered
2015-10-19
Start date
2016-01-31
Completion date
2017-06-30
Last updated
2017-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Expectancy, Pain, Placebo Effect

Brief summary

To date, very little is known about the mechanisms of open-label placebo treatment and there is a lack in highly controlled experimental designs. Therefore, the planned project will test well-established explanatory models of (deceptive) placebo, i.e., (1) expectancy, (2) meaning response, in an open-label placebo design, investigating their influence on placebo analgesia.

Detailed description

The current project will consist of one experimental study and one qualitative study: 1. the effects of open-label, and deceptive placebo administration on placebo analgesia will be directly compared when both groups have a comparable expectancy-inducing scientific rationale; 2. subjective meaning models will be assessed by comparing subjective narratives of the placebo effect in open-label and deceptive placebo groups in a nested qualitative study. The experimental study will be a randomized experiment with healthy subjects (N=120), and pain will be induced using a standardized heat pain paradigm (Medoc, Ramatishai, Israel; thermo-sensory analyzer (TSA)-II). Effects of the experimental conditions will be assessed both objectively (i.e. heat pain threshold and tolerance) and subjectively (i.e. subjective pain ratings, pain intensity and unpleasantness). Furthermore, investigators will randomly select 30 participants to take part in a nested qualitative study in order to qualitatively assess the meaning response by comparing subjective narratives of the placebo effect in the open-label and deceptive placebo groups, as well as in the control group.

Interventions

Placebo Cream, openly described as Placebo

OTHERdeceptive placebo

Placebo Cream, described as Voltaren, containing Diclofenac

Sponsors

University Hospital, Basel, Switzerland
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy male and female adults aged 18-65 * Healthy by self-report statement, thus no known current or chronic somatic diseases or psychiatric disorders * Right-handedness (Oldfield, 1971), * Willing to participate in study

Exclusion criteria

* Medicine or Psychology Students * Any acute or chronic disease (chronic pain, hypertension, heart disease, renal disease, liver disease, diabetes) as well as skin pathologies, neuropathies or nerve entrapment symptoms, sensory abnormalities affecting the tactile or thermal modality * Current medications (psychoactive medication, narcotics, intake of analgesics) or being currently in psychological or psychiatric treatment * Insufficient German language skills to understand the instructions * Previous participation in studies using pain assessment (threshold and tolerance) with Peltier Devices * Daily consumption of more than three alcoholic standard beverages per day (a standard alcoholic beverage is defined as either 3dl beer or 1 dl wine or 2cl spirits) * Current or regular drug consumption (THC, cocaine, heroin, etc.)

Design outcomes

Primary

MeasureTime frameDescription
subjective intensity and unpleasantness ratings of heat pain tolerance2 hoursVisual Analogue Scale (VAS)
objective heat pain tolerance2 hoursTemperatures

Secondary

MeasureTime frameDescription
multidimensional sensitivities questionnaire (Mehrdimensionaler Befindlichkeitsfragebogen (MDBF))2 hours
sociodemographic questionnaire (Soziodemographischer Fragebogen (SDD))2 hours
Revised Life Orientation Test (LOT-R)2 hours
NEO five-factor inventory (NEO-FFI)2 hours
questionnaire on competence and locus of control (Fragebogen zu Kompetenz- und Kontrollüberzeugungen (FKK))2 hours
Expectancy of Relief Scale (ERS; Erwartungsfragebogen)2 hours
Beliefs in holistic health and holistic treatments; Complementary and Alternative Medicine Beliefs Intentory (CAMBI)2 hours
Desire for Relief Scale (DRS)2 hours
subjective intensity and unpleasantness ratings of heat pain threshold2 hoursVisual Analogue Scale (VAS)
objective heat pain threshold2 hoursTemperatures
Anxiety and Depression Scale (HADS-D)2 hours
Credibility and Effectiveness of the placebo analgesia expectation; adapted Version of the Context Model Questionnaire; Kontextmodellfragebogen (KMF)2 hours

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026